T-cell receptor binding major histocompatibility complex-peptide complex (null)

The **T-cell receptor binding major histocompatibility complex-peptide complex** (TCR–pMHC) is a critical trimeric complex at the heart of adaptive immunity. It consists of the T-cell receptor (TCR) on the surface of T lymphocytes specifically recognizing antigenic peptide fragments presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[1][2][3][5]. The proper engagement of the TCR with the peptide–MHC complex is essential for the activation of T cells, which drives immune responses against pathogens, cancers, and, in pathologic settings, self-antigens. Recognition is governed by both the structural fit and affinity between the TCR and the pMHC, and subtle differences in the peptide or MHC can determine the outcome of T cell activation or tolerance[1][3][4][5]. This molecular interaction is the central focus for many immunotherapies, including cancer immunotherapy and engineered T-cell therapies, but presents significant safety challenges due to the risk of cross-reactivity and unintended recognition of self-peptides[5]. The study and therapeutic manipulation of TCR–pMHC complexes are therefore essential for understanding immune specificity, developing personalized vaccines, and designing next-generation cellular therapies[1][3][5][6].

Other names

TCR–peptide–MHC complexTCR–pMHC complexT-cell receptor–peptide–MHC complexTCR–pepMHC

Direct blocking or mimicking of TCR–pMHC binding to control T cell recognition Enhancing TCR signaling via affinity-engineered TCRs (as in adoptive therapies) Redirecting T cells toward specific peptide–MHC targets (e.g., bispecifics or engineered T cells)